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Edited by Jacomine Krijnse-LockerAbstract The conserved, aromatic-rich membrane-proximal
external region (MPER) of gp41 is functional in human immuno-
deﬁciency virus (HIV)-cell fusion by perturbing membrane integ-
rity. Broadly-neutralizing 2F5 and 4E10 monoclonal antibodies
(MAb-s) recognize amino- and carboxy-terminal epitope se-
quences within this domain, respectively. An MPER peptide
overlapping 2F5 and 4E10 epitope sequences was capable of
breaching the permeability barrier of lipid vesicles. Cholesterol
and sphingomyelin raft-lipids, present at high quantities in the
HIV-1 envelope, promoted exposure or occlusion of 4E10 epi-
tope, respectively. Conversely, 2F5 epitope accessibility was af-
fected to a lesser extent by these envelope lipids. These
observations support the idea that MPER epitopes on mem-
branes are segmented in terms of how they are aﬀected by enve-
lope lipids, which may have implications for MPER-based
vaccine development.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The potential to elicit broadly neutralizing antibodies (NAb-
s) is a long-pursued goal for an human immunodeﬁciency virus
type-1 (HIV-1) vaccine [1]. Monoclonal antibodies (MAb-s)
2F5 and 4E10 are one of the few examples of identiﬁed
NAb-s showing capacity to neutralize a broad spectrum of
HIV-1 clades and primary isolates [2–7]. These NAb-s have
evolved to recognize epitopes within the membrane-proximalAbbreviations: Chol, cholesterol; CRAC, Cholesterol Recognition/
interaction Amino acid Consensus motif; DPC, dodecylphosphocho-
line; HIV-1, human immunodeﬁciency virus type-1; MAb, monoclonal
antibody; MPER, membrane-proximal external region; NAb-s, neu-
tralizing antibodies; POPC, phosphatidylcholine; PL, phospholipid;
PreTM, pretransmembrane; SPM, sphingomyelin; WW, Wimley–
White
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doi:10.1016/j.febslet.2008.10.012external region (MPER), preceding the envelope gp41 sub-
units transmembrane domain. Thus, MPER constitutes a can-
didate target vaccine for the development of antibodies that
can neutralize the wide array of circulating HIV-1 isolates
[8,9].
Based on a site-directed mutagenesis study, Salzwedel et al.
[10] deﬁned MPER as the aromatic-rich, conserved gp41se-
quence 665KWASLWNWFNITNWLWYIK683. This domain
was primarily implicated in gp41-induced membrane fusion
and envelope glycoprotein incorporation into virions [10,11].
The same gp41 sequence was designated as the pretransmem-
brane (PreTM) domain according to its tendency to stably
associate with the membrane interface as an a-helix and pro-
mote lipid vesicle destabilization [12–14]. The interfacial loca-
tion of the helical MPER/PreTM sequence was subsequently
supported by structural studies [15–17]. Additionally, viral
envelope raft-lipids such as cholesterol (Chol) and sphingomy-
elin (SPM) were shown to modulate MPER capacity to desta-
bilize membranes [14,18,19]. Experimental evidence and
modeling studies further supported MPER–Chol interactions
through the carboxy-terminal ‘‘Cholesterol Recognition/inter-
action Amino acid Consensus’’ (CRAC) LWYIK motif
[20,21]. Just recently, Vishwanathan and Hunter [22] replaced
MPER with indolicidin-based sequences. Indolicidin is a Trp-
rich, antimicrobial peptide that forms pores in membranes.
Some of the produced gp41 chimeras retained fusion activity,
suggesting that membrane-perturbing properties are key to
MPER membrane fusion function [22].
Thus, the experimental evidence produced in cells and model
systems supports MPER function in fusion (recently reviewed
in [23]). Attending to this evidence it has been hypothesized
that NMAb-s 2F5 and 4E10 might neutralize the virus by
blocking membrane-perturbing MPER activity [17,24]. In sup-
port of this hypothesis MAb-s 2F5 and 4E10 are adapted for
recognition of membrane embedded MPER sequences
[17,24–29]. Recent experiments described by Sun et al. [17]
demonstrate that MAb4E10 binds to membrane-embedded
MPER and induces its partial extraction. These authors postu-
late that the solved structure of MPER inserted into dod-
ecylphosphocholine (DPC) micelles represents a minimal
native-like gp41 structure with the potential of eliciting
NAb-s. Accordingly, it has been suggested that MPER-derived
peptides in a lipid environment might constitute useful plat-
forms for purposes of vaccine design [17,24,29].
Here, in search for a minimal lipid composition allowing
simultaneous and eﬀective presentation of 2F5 and 4E10
epitopes at the membrane interface, we have comparativelyblished by Elsevier B.V. All rights reserved.
N. Huarte et al. / FEBS Letters 582 (2008) 3798–3804 3799analyzed the eﬀects of SPM and Chol, the main raft-lipids
existing in the viral envelope [19]. Eﬀective binding has been
derived from the antibody-induced inhibition of the MPER
membrane-perturbing activity measured in solution-diﬀusing
lipid vesicles [24]. Since the MPER native-like structure rele-
vant for antibody recognition has been solved in contact with
a phosphocholine-based lipid [17], the vesicles used in this
study as a reference were made of pure phosphatidylcholine
(POPC). Our results suggest that the lipid environment aﬀects
predominantly 4E10 epitope accessibility. This observation
might guide the development of immunogens combining
MPER with a minimal amount of chemically deﬁned lipids.Fig. 1. Deﬁnition and membrane-perturbing properties of AISpreTM
peptide. (A) Schematic diagram to designate gp41 regions: FP, fusion
peptide; NHR and CHR, amino- and carboxy-terminal helical regions,
respectively; MPER, membrane-proximal external region; TMD
transmembrane domain. AISpreTM (below) spans the 656–683 region
that contains 2F5 and 4E10 epitopes. Boxes designate crucial residues
according to Zwick et al. [36] mutated by Ala in AISpreTM(9,10)A
and AISpreTM(17,18)A peptides. (B) Percentage of AISpreTM-
induced leakage after 30 min of incubation with vesicles, plotted as a
function of the peptide-to-lipid mole ratio (Ri). Filled circles and
continuous line: POPC:SPM (1:1 mol:mol); ﬁlled squares and dotted
line: POPC; and empty circles and slashed line: POPC:Chol(2:1 mol:-
mol). Arrows indicate the conditions selected to measure MAb-
induced blocking of leakage. Final lipid concentration was 0.1 mM in
all cases.2. Materials and methods
NEQELLELDKWASLWNWFNITNWLWYIK (AISpreTM), NEQ-
ELLELAAWASLWNWFNITNWLWYIK (AISpreTM(9,10)A) and
NEQELLELDKWASLWNAANITNWLWYIK (AISpreTM(17,18)A)
peptides were synthesized by solid-phase synthesis using Fmoc
chemistry, as C-terminal carboxamides and puriﬁed by HPLC at the
Proteomics Unit of the University Pompeu-Fabra (Barcelona, Spain).
Peptide stock solutions were prepared in dimethylsulfoxide (DMSO)
(spectroscopy grade) and concentrations determined by Bicinchoninic
Acid microassay (Pierce, Rockford, IL, USA). NAb expressing hybrid-
omas were originally generated by a combined PEG-electrofusion of
peripheral blood mononuclear cells of HIV infected non-symptomatic
patients [2]. MAb-s 2F5 and 4E10 used in this study were subsequently
produced in recombinant CHO cells after subclass switch to IgG1 [30].
1-Palmitoyl-2-oleoylphosphatidylcholine (POPC), SPM, 1-palmitoyl-
2-stearoyl(6,7)dibromo-sn-glycero-3-phosphocholine (Br6-PSPC) and
1-palmitoyl-2-stearoyl(11,12)dibromo-sn-glycero-3-phosphocholine (Br11-
PSPC) were purchased from Avanti Polar Lipids (Birmingham, AL,
USA). 8-Aminonaphtalene-1,3,6-trisulfonic acid sodium salt (ANTS)
and p-xylenebis(pyridinium)bromide (DPX) were from Molecular
Probes (Junction City, OR, USA).
Large unilamellar vesicles (LUV) were prepared following the extru-
sion method of Hope et al. [31] in 5 mM Hepes, 100 mM NaCl (pH
7.4) buﬀer and using polycarbonate membranes (Nuclepore Inc., Pleas-
anton, CA, USA) with a 0.1 lm nominal pore size. Lipid concentra-
tions of liposome suspensions were determined by phosphate
analysis. Release of encapsulated vesicular contents to the medium
was ﬂuorimetrically monitored by the ANTS/DPX assay [32] as previ-
ously described [27]. Kinetics of membrane-insertion were measured by
energy transfer from peptide-Trp to the surface ﬂuorescent probe d-
DHPE as described [24].
Penetration level of the peptide into the bilayer core was inferred
from the Trp ﬂuorescence quenching by the hydrophobic matrix-resid-
ing brominated phospholipids (PLs), according to the method de-
scribed by Bolen and Holloway [33]. These experiments were carried
out using sonicated vesicles containing a POPC fraction substituted
for the brominated PLs Br6-PSPC or Br11-PSPC.
Circular dichroism (CD) measurements were obtained from a ther-
mally-controlled Jasco J-810 CD spectropolarimeter calibrated rou-
tinely with (1S)-(+)-10-camphorsulfonic acid, ammonium salt.
Samples consisted of co-lyophilized peptide and lipid dissolved and
sonicated in 2 mM Hepes (pH, 7.4) buﬀer. Spectra were measured in
a 1 mm path-length quartz cell initially equilibrated at 25 C. Data
were taken with a 1 nm band-width at 100 nm/min speed, and the re-
sults of 20 scans were averaged.
For the enzyme-linked immunosorbent assay (ELISA), peptides
were dissolved in phosphate-buﬀered saline (PBS) and immobilized
(100 ml/well) overnight in C96 Maxisorp microplate wells (Nunc, Den-
mark) at a concentration of 1 lM. Prior to incubation with the MAbs,
the plates were blocked for 2 h with 3% (w/v) bovine-serum albumin in
PBS. The binding of the Mabs was detected with an alkaline phospha-
tase-conjugated goat anti-human immunoglobulin (Pierce, Rockford,
IL, USA), which then catalyzed a color reaction with the p-nitrophenyl
phosphate substrate (Sigma, St. Louis, MO, USA) that could be mea-
sured by absorbance at a wavelength of 405 nm in a Synergy HT
microplate reader (Bio-TEK Instruments Inc., VT, USA).3. Results
3.1. Lipid eﬀects on AISpreTM-induced leakage
Predictive tools based on the use of Wimley–White (WW)
water-to-membrane interface transfer free energies [34] and re-
cent structural characterization suggest that membrane-bound
MPER/PreTM is segmented into two subdomains [14,17]. The
N-terminal domain comprises a helical, conserved amphi-
pathic-at-interface sequence (AIS). AIS is followed by a fully
hydrophobic-at-interface stretch that precedes the transmem-
brane anchor. The AISpreTM peptide used in this study was
designed to contain both interfacial subdomains ( Fig. 1A).
In addition, AISpreTM encompasses the full-length 2F5 and
4E10 epitopes [26,35]. Consistent with its predicted role in fu-
sion, this MPER peptide was capable of breaching the mem-
brane permeability barrier of lipid vesicles (Fig. 1B).
In a previous contribution we showed that the lytic activity
of HIVc, a shorter MPER peptide devoid of NEQELLEL AIS
residues, was dependent on the presence of SPM [18]. Thus,
low amounts of peptide were required to permeabilize
POPC:SPM (1:1 mol:mol) vesicles (in the order of 1:1000–
1:10000 peptide-to-lipid ratios) and the process could be mod-
eled according to a pore-formation phenomenon. Relatively
much higher doses were required to permeabilize POPC or
POPC:Chol (2:1 mol:mol) vesicles (in the order of 1:10–1:200
peptide-to-lipid ratios) and kinetic modeling ruled out pore-
formation as the permeabilization mechanism in those sys-
tems. AISpreTM lytic activity was also stimulated upon addi-
tion of SPM to the liposome composition (Fig. 1B). Peptide-to-
lipid mole ratios in the order of 1:1000 were required to totally
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son ca. 10 times higher peptide doses were required to permea-
bilize pure POPC or POPC:Chol (2:1 mole ratio) LUV. This
observation conﬁrmed previous results indicating that
PreTM/MPER activity was preserved in the longer AISpreTM
peptide [24].
The CD results displayed in Fig. 2A revealed similar second-
ary structures for AISpreTM in contact with POPC,
POPC:SPM (1:1) and POPC:Chol (2.1) vesicles. The CD spec-
tra obtained in the three systems displayed major band compo-
nents at 208 and 222 nm supporting that the helical
conformation was the main structure adopted by the peptide.
Thus, the adoption of a distinct lytic secondary structure by
the peptide did not provide an explanation for the leakage
enhancement observed in the presence of SPM (Fig. 1). The
intrinsic ﬂuorescence results below (Fig. 2B) suggested that
AISpreTM may insert deeper into POPC and POPC:SPM
(1:1) than into POPC:Chol (2:1) bilayers. In the case of
POPC:SPM and POPC vesicles AISpreTM-Trp-s were
quenched to similar extents by Br6-PSPC and Br11-PSPC (left
and center panels). In contrast, Br6-PSPC quenched AIS-
preTM-Trp emission more eﬃciently than Br11-PSPC (right
panel). Bromine atoms quench by a short range process that
requires a close approach to the ﬂuorophore [33]. Thus, AIS-
preTM Trp residues located closer to the C6–C7 than to the
C11–C12 position within the acyl chain region of the bilayers
containing Chol. In conclusion, Chol seemed to induce a shal-
lower peptide insertion into the lipid bilayer, but did not
appreciably aﬀect its overall secondary structure.Fig. 2. Interaction of AISpreTM with POPC:SPM (1:1 mole ratio), POPC
AISpreTM peptide associated to the vesicles (lipid concentration, 1 mM).
ﬂuorescence emission spectra of AISpreTM incubated with the same type of
traces below correspond to spectra obtained in the presence of vesicles in wh
PSPOPC, respectively. The ﬁnal brominated lipid content in all vesicles was
lipid mole ratios were 1:500 (POPC:SPM) and 1:100 (POPC and POPC:Cho3.2. Lipid eﬀects on speciﬁc recognition and blocking of
AISpreTM
AISpreTM-induced vesicle permeabilization was next used
to assess the inﬂuence of SPM and Chol on antibody-induced
inhibition of MPER membrane activity (Fig. 3). Panel 3A illus-
trates the eﬀect of MAb addition to the ongoing AISpreTM-
induced leakage in vesicles of diﬀerent lipid composition. In
all cases, kinetic traces of d-DHPE ﬂuorescence increase dem-
onstrated faster peptide incorporation into vesicles (dotted
traces). AISpreTM was added to a stirred solution of lipid ves-
icles (1), left suﬃcient time for incorporation into them, and
MAb was subsequently injected into the mixture (2). Consis-
tent with recognition of membrane-bound species under these
conditions, addition of MAb-s 4E10 and 2F5 arrested the leak-
age process (top and bottom panels, respectively). However, as
compared to that induced by MAb2F5, MAb4E10 addition in-
duced a weaker inhibition of leakage from POPC:SPM vesicles
(left panels).
The dose dependence of leakage inhibition illustrates further
this eﬀect (panel B). The inhibition percentages were calculated
from the leakage extents measured after 5 min of incubation,
and using as 0% inhibition reference vesicle samples untreated
with MAb. Relatively lower doses of MAb4E10 than of
MAb2F5 were required to eﬀectively arrest AISpreTM-in-
duced leakage in POPC and POPC:Chol vesicles. Moreover,
Chol promoted the inhibitory capacity of MAb4E10. In con-
trast, the capacity of MAb4E10 to block AISpreTM was im-
paired in POPC:SPM vesicles. In this system Mab2F5
actually inhibited AISpreTM activity more eﬃciently thanand POPC:Chol (2:1 mole ratio) lipid vesicles. (A) CD spectra of
The concentration of AISpreTM peptide was 30 lM. (B) Intrinsic
vesicles (traces on top labeled with symbols). Continuous and dotted
ich a fraction of the POPC was substituted for Br6-PSPOPC or Br11-
25 mol%. Vesicle lipid concentration was 0.1 mM and the peptide-to-
l).
Figure 3. Inhibition of AISpreTM-induced vesicle contents leakage by MAb-s 2F5 and 4E10. (A) Eﬀect of Mab addition to the ongoing leakage.
Vesicle samples (100 lM lipid) were treated with 0.2 (POPC:SPM) or 1 lM (POPC and POPC:Chol) AISPreTM and, subsequently supplemented
with 50 lg/ml of MAb-s 2F5 or 4E10 (addition times indicated by ‘‘1’’ and ‘‘2’’, respectively). The dotted traces follow AISpreTM incorporation into
the vesicles monitored through energy transfer from peptide tryptophans to membrane-residing d-DHPE. Addition of the antibody results in a
sudden decrease of the leakage rate. The traces labeled with (+) and (–) correspond to the leakage kinetics in the presence and the absence of
antibody, respectively. (B) Dose dependency of AISpreTM-induced leakage inhibition by MAb4E10 or MAb2F5 in POPC:SPM (ﬁlled circles and
continuous lines) POPC (squares and dotted lines) and POPC:Chol (hollow circles and slashed lines) vesicles. Inhibition percentages, calculated from
the extents of leakage after 5 min, were plotted as a function of MAb paratope:peptide mole ratio.
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nounced eﬀect on MAb2F5 inhibitory activity.
The previous results suggest that Chol and SPM can modu-
late membrane-inserted epitope binding, the eﬀect being more
drastic for the MAb4E10 than for the MAb2F5. Speciﬁc
epitope recognition involvement in the blocking of AIS-
preTM-induced leakage in POPC:Chol was previously demon-
strated using sequences with Ala substituting for crucial
residues Asp9 and Lys10, or Trp17 and Phe18 [24,36]. The
resulting AISpreTM(9,10)A and AISpreTM(17,18)A peptides
functioned as speciﬁcity controls for Mab2F5 and Mab4E10,
respectively. The data shown in Fig. 4 support that also block-
ing of the AISpreTM-induced leakage in POPC:SPM vesicles
evolved as a consequence of speciﬁc epitope recognition.
MAb eﬀect on the kinetics of leakage induced by AISpre-
TM(9,10)A and AISpreTM(17,18)A peptides in POPC:SPM
vesicles is displayed in panel A. MAb4E10 blocked AIS-
preTM(9,10)A-induced leakage, albeit ineﬃciently, but had al-
most no eﬀect on AISpreTM(17,18)A-induced leakage (blue
traces). Conversely, MAb2F5 arrested AISpreTM(17,18)A-in-
duced leakage eﬃciently but had almost no eﬀect on the pro-
cess induced by the AISpreTM(9,10)A variant (red traces).Panel B surveys results of speciﬁcity experiments that com-
pare binding to these peptides inserted into POPC:SPM vesi-
cles or directly bound to ELISA plates. MAb4E10 binding
(blue bars) was speciﬁc for the AISpreTM(9,10)A sequence
in POPC:SPM vesicles, following a pattern similar to that ob-
served for the peptides adsorbed to ELISA plates. Conversely,
Mab2F5 bound to AISpreTM(17,18)A, but not to AIS-
preTM(9,10)A, both in vesicles and ELISA plates. Thus, even
if mechanistically diﬀerent membrane perturbations are ex-
pected to be promoted by AISpreTM in Chol or SPM-contain-
ing membranes (see Refs. [18,27]), MAb2F5 and Mab4E10
were capable to speciﬁcally recognize their epitopes and block
membrane destabilization in the presence of both lipids.4. Discussion
NMAb-s are potent tools in HIV-1 vaccine design [7]. It has
been argued that NMAb aﬃnity per se is not the single deter-
minant of neutralization [7,17]. We have recently proposed
that the inhibition of membrane-perturbing MPER activity
might correlate with the biological potency of anti-gp41 2F5
Fig. 4. Dependence of MAb-induced POPC:SPM vesicle leakage
blocking on speciﬁc epitope recognition. (A) Blocking by MAb2F5
(red traces) and Mab4E10 (blue traces) of leakage induced by the
addition of 0.2 lM AISpreTM(9,10)A (left panel) or AIS-
preTM(17,18)A (right panel) to POPC:SPM vesicles. Black trace
corresponds to the control without MAb. MAbs were added at the
concentration of 50 lg/ml. For better appreciation of the eﬀect, only
the kinetic trace section after Mab addition is shown. (B) Left panel:
inhibition of leakage induced by 0.2 lM AISpreTM(9,10)A or
AISpreTM(17,18)A in POPC:SPM vesicles. Right panel: binding
measured by ELISA in plates with 1 lM AISpreTM(9,10)A or
AISpreTM(17,18)A. MAb2F5 (red bars) and Mab4E10 (blue bars)
were added at the concentrations of 50 and 1 lg/ml in the vesicle assay
and ELISA, respectively.
Fig. 5. Model for MPER interaction with lipid bilayers containing
Chol (a) or SPM (b). See text for details.
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extraction mechanism proposed by Sun et al. [17], Mab-s
2F5 and 4E10 blocked bilayer-destabilizing MPER activity
in PC vesicles. The inclusion of SPM reduced signiﬁcantly
the apparent aﬃnity of MAb4E10 for AISpreTM under condi-
tions promoting pore-formation. Conversely, Chol induced
shallower AISpreTM insertion into the bilayer and higher
MAb4E10 aﬃnity, thus supporting that recognition mainly
evolves upon exposure of the 4E10 epitope at the level of the
membrane interface. In contrast, Mab2F5 capacity for block-
ing MPER activity was less aﬀected by the membrane compo-
sition, suggesting that 2F5 epitope accessibility was similar
under all conditions.
This diﬀerential lipid eﬀect on membrane-bound epitope
accessibility is likely to originate from MPER segmentation
into two topologically distinct interfacial subdomains
[14,17,23]. In one hand, 2F5 epitope 657EQELLELDK-
WASLW670 sequence (red cylinders in the models depicted
in Fig. 5) appears to remain anchored to the water–membrane
interface and more accessible for antibody binding even under
conditions that promote lytic pore-formation. On the other
hand, exposure of 4E10 epitope 672WFNITNWLW680 se-
quence (green cylinders in the models depicted in Fig. 5), pre-
dicted to insert more deeply into the membrane interface
region, appears to be distinctly aﬀected by Chol or SPM.AISpreTM seems to insert less deeply into the lipid bilayer in
the presence of Chol, which might increase 4E10 epitope acces-
sibility for antibody binding (Fig. 5a). Supporting this explana-
tion, the extended 4E10 epitope includes a helical turn
involving L679 and W680 residues [35,37], which overlaps par-
tially with the 679LWYIK683 CRAC motif [20,21,38]. Thus, it
might well be that MPER interacting with Chol through the
CRAC domain provides the optimal conditions for Mab4E10
binding. Furthermore, the MPER sequence positioned into the
interface might exert its bilayer perturbing activity by disrupt-
ing interactions between lipid molecules and/or by inducing
membrane deformation and thinning. Conversely, SPM has
been described to promote lytic-pore formation [23]. It appears
that accessibility to the MPER stretch spanned by the 4E10
epitope is restrained within the pores promoted by this lipid
(Fig. 5b).
These observations support the proposal that lipid-modula-
tion of MPER interaction might partially explain the discrep-
ancy in MAb4E10 antibody neutralization eﬃciency for the
same virus, produced in 293T cells versus peripheral blood
mononuclear cells [7,17]. Circulating blood lymphocyte lipid
composition is comparable to that of the MT-4 T-cell line used
by Bru¨gger et al. to analyze the HIV lipid constituents [19,39].
Virions produced in both types of cells are therefore predicted
to bear a similar SPM/PC ratio. However, a signiﬁcantly high-
er SPM/PC ratio of ca. 2 was determined for virions produced
in MT-4 cells as compared to the value of 0.5 reported for HIV
pseudotypes produced in 293T cells [40]. Thus a reduction in
the SPM content with respect to PC could conceivably explain,
at least in part, the higher neutralization eﬃciency of
MAb4E10 for the same virus produced in 293T cells.
Finally, the results described in this work might have a direct
application to the development of immunogens combining
MPER peptides with lipids. For economic, safety and repro-
N. Huarte et al. / FEBS Letters 582 (2008) 3798–3804 3803ducibility reasons, a useful formulation will be probably based
on a minimal number of deﬁned lipid species. Our data on
MAb-induced MPER activity inhibition suggest that the eﬃ-
cient and simultaneous presentation of 2F5 and 4E10 epitopes
in a membrane environment might be optimally attained in li-
pid bilayers combining PC and Chol.
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